Federal Register of Legislation - Australian Government

Primary content

PB 65 of 2012 Arrangements as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (No. PB 79 of 2011) to make changes to the efficient funding of chemotherapy.
Administered by: Health
Registered 21 Aug 2012
Tabling HistoryDate
Tabled HR22-Aug-2012
Tabled Senate22-Aug-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 65 of 2012

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 7)

 

National Health Act 1953

___________________________________________________________________________

 

I, STEVE DUNLOP, Assistant Secretary A/g, Pharmaceutical Programs and Support Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 16 /8/2012

 

 

 

 

 

 

 

 

 

 

 

STEVE DUNLOP

Assistant Secretary A/g

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 7).

 

(2)                This Instrument may also be cited as PB 65 of 2012.

 

2             Commencement

                This Instrument commences on 1 September 2012.

3              Amendments to PB 79 of 2011

                 Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

 

 


Schedule 1                   Amendments

 

 

 

[1]    Schedule 1 Part 1, entry for Docetaxel

omit:

Docetaxel

Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) in 0.5 mL with solvent

 Injection

Taxotere

SW

MP

C3186 C3888 C3890 C3892 C3916 C3955

C3956

C7002

D

 

Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) in 2 mL with solvent

 Injection

Taxotere

SW

MP

C3186 C3888 C3890 C3892 C3916 C3955

C3956

C7002

D

substitute:

Docetaxel

Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) in 2 mL with solvent

 Injection

Taxotere

SW

MP

C3186 C3888 C3890 C3892 C3916 C3955

C3956

C7002

D

 

[2]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand Docetaxel Sandoz, in the column headed ‘Circumstances’

Insert after C3890:

C3892

 

 

[3]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand Docetaxel Sandoz, in the column headed ‘Circumstances’

Insert after C3890:

C3892

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.